

# Oliver Distler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2656353/publications.pdf>

Version: 2024-02-01

488  
papers

34,210  
citations

3874

91  
h-index

6024

165  
g-index

504  
all docs

504  
docs citations

504  
times ranked

27545  
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to: "Correspondence on "Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSICIS trial" by Bredemeier. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e251-e251.	0.5	0
2	Response to: "Riociguat in systemic sclerosis: a potential for disease modification" by Jain and Dhir. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e117-e117.	0.5	0
3	Secondary attack rates from asymptomatic and symptomatic influenza virus shedders in hospitals: Results from the TransFLUas influenza transmission study. <i>Infection Control and Hospital Epidemiology</i> , 2022, 43, 312-318.	1.0	9
4	Representativeness of systemic sclerosis patients in interventional randomized trials: an analysis of the EUSTAR database. <i>Rheumatology</i> , 2022, 61, 743-755.	0.9	5
5	Digital pitting scars are associated with a severe disease course and death in systemic sclerosis: a study from the EUSTAR cohort. <i>Rheumatology</i> , 2022, 61, 1141-1147.	0.9	8
6	Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score. <i>Arthritis and Rheumatology</i> , 2022, 74, 518-526.	2.9	21
7	Patients with systemic sclerosis show phenotypic and functional defects in neutrophils. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1274-1284.	2.7	8
8	TNF $\alpha$ induces endothelial dysfunction in rheumatoid arthritis via LOX-1 and arginase 2: reversal by monoclonal TNF $\alpha$ antibodies. <i>Cardiovascular Research</i> , 2022, 118, 254-266.	1.8	13
9	Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry. <i>European Respiratory Journal</i> , 2022, 59, 2102024.	3.1	57
10	Computed tomography-based radiomics decodes prognostic and molecular differences in interstitial lung disease related to systemic sclerosis. <i>European Respiratory Journal</i> , 2022, 59, 2004503.	3.1	26
11	COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2022, 60, 2102311.	3.1	124
12	COVID-19 vaccination in autoimmune disease (COVAD) survey protocol. <i>Rheumatology International</i> , 2022, 42, 23-29.	1.5	37
13	Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (SclerID) questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 507-515.	0.5	10
14	Skin biomarkers associated with complex regional pain syndrome (CRPS) Type I: a systematic review. <i>Rheumatology International</i> , 2022, 42, 937-947.	1.5	4
15	Role of synovial fibroblast subsets across synovial pathotypes in rheumatoid arthritis: a deconvolution analysis. <i>RMD Open</i> , 2022, 8, e001949.	1.8	23
16	Acrylonitrile and Pullulan Based Nanofiber Mats as Easily Accessible Scaffolds for 3D Skin Cell Models Containing Primary Cells. <i>Cells</i> , 2022, 11, 445.	1.8	2
17	Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 168-178.	1.0	9
18	Current differentiation between radiographic and non-radiographic axial spondyloarthritis is of limited benefit for prediction of important clinical outcomes: data from a large, prospective, observational cohort. <i>RMD Open</i> , 2022, 8, e002067.	1.8	11

#	ARTICLE	IF	CITATIONS
19	Detect-and-segment: A deep learning approach to automate wound image segmentation. Informatics in Medicine Unlocked, 2022, 29, 100884.	1.9	23
20	Vaccine hesitancy in patients with autoimmune diseases: Data from the coronavirus disease-2019 vaccination in autoimmune diseases study. Indian Journal of Rheumatology, 2022, 17, 188.	0.2	14
21	Self-monitoring of the resting heart rate using a fitness tracker smartwatch application leads to an early diagnosis of large vessel vasculitis. BMJ Case Reports, 2022, 15, e245021.	0.2	2
22	Nintedanib in Patients With Autoimmune Diseaseâ€“Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the <sc>INBUILD</sc> Trial. Arthritis and Rheumatology, 2022, 74, 1039-1047.	2.9	44
23	Is there a role for nailfold videocapillaroscopy in interstitial lung disease?. Rheumatology, 2022, , .	0.9	3
24	Nailfold capillaroscopy in SSc: innocent bystander or promising biomarker for novel severe organ involvement/progression?. Rheumatology, 2022, 61, 4384-4396.	0.9	10
25	Should Degenerated Intervertebral Discs of Patients with Modic Type 1 Changes Be Treated with Mesenchymal Stem Cells?. International Journal of Molecular Sciences, 2022, 23, 2721.	1.8	6
26	Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment. Rheumatology, 2022, 61, 4035-4046.	0.9	6
27	Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis. Journal of Heart and Lung Transplantation, 2022, 41, 971-981.	0.3	9
28	Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort. Rheumatology, 2022, 61, 4786-4796.	0.9	20
29	Sarcoidosis - a multisystem disease.. Swiss Medical Weekly, 2022, 152, w30049.	0.8	1
30	An Optimized Tissue Dissociation Protocol for Single-Cell RNA Sequencing Analysis of Fresh and Cultured Human Skin Biopsies. Frontiers in Cell and Developmental Biology, 2022, 10, 872688.	1.8	12
31	Calcineurin inhibitors in systemic sclerosis â€“ a systematic literature review. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210923.	1.2	1
32	Potential of Photon-Counting Detector CT for Radiation Dose Reduction for the Assessment of Interstitial Lung Disease in Patients With Systemic Sclerosis. Investigative Radiology, 2022, 57, 773-779.	3.5	31
33	COVID-19 vaccination-related adverse events among autoimmune disease patients: results from the COVAD study. Rheumatology, 2022, 62, 65-76.	0.9	19
34	Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis. Lancet Respiratory Medicine, 2022, 10, 937-948.	5.2	57
35	Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSICIS trial compared with healthy reference subjects. Respiratory Research, 2022, 23, .	1.4	1
36	Prediction of histology by B-mode and PD-mode ultrasound across different joint locations and diseases. RMD Open, 2022, 8, e002439.	1.8	0

#	ARTICLE	IF	CITATIONS
37	The Challenge of Very Early Systemic Sclerosis: A Combination of Mild and Early Disease?. <i>Journal of Rheumatology</i> , 2021, 48, 82-86.	1.0	15
38	Bone Mineral Density Quantification from Localizer Radiographs: Accuracy and Precision of Energy-integrating Detector CT and Photon-counting Detector CT. <i>Radiology</i> , 2021, 298, 147-152.	3.6	18
39	Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 143-150.	0.5	120
40	Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 238-241.	0.5	54
41	Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 219-227.	0.5	160
42	Reporting items for capillaroscopy in clinical research on musculoskeletal diseases: a systematic review and international Delphi consensus. <i>Rheumatology</i> , 2021, 60, 1410-1418.	0.9	20
43	The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Expertsâ€™ Consensus. <i>Autoimmunity Reviews</i> , 2021, 20, 102738.	2.5	38
44	COVID-19 and systemic sclerosis: Rising to the challenge of a pandemic. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 58-65.	1.0	17
45	Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review. <i>ERJ Open Research</i> , 2021, 7, 00235-2020.	1.1	11
46	Serotonin and Fibrosis. <i>Receptors</i> , 2021, , 231-246.	0.2	0
47	Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSICIS trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 96-106.	5.2	118
48	The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. <i>Rheumatology</i> , 2021, 60, 5028-5041.	0.9	34
49	No Evidence for a Decrease in Physical Activity Among Swiss Office Workers During COVID-19: A Longitudinal Study. <i>Frontiers in Psychology</i> , 2021, 12, 620307.	1.1	20
50	The AP-1 Transcription Factor Fosl-2 Regulates Autophagy in Cardiac Fibroblasts during Myocardial Fibrogenesis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1861.	1.8	16
51	<sup>68</sup> Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study. <i>Lancet Rheumatology</i> , The, 2021, 3, e185-e194.	2.2	46
52	Circulating collagen neo-epitopes and their role in the prediction of fibrosis in patients with systemic sclerosis: a multicentre cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e175-e184.	2.2	13
53	Assessment of Bone Mineral Density From a Computed Tomography Topogram of Photon-Counting Detector Computed Tomographyâ€™Effect of Phantom Size and Tube Voltage. <i>Investigative Radiology</i> , 2021, 56, 614-620.	3.5	6
54	Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 instrument as a clinical decision aid in the routine clinical care of patients with systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2021, 23, 125.	1.6	5

#	ARTICLE	IF	CITATIONS
55	No evidence for an effect of working from home on neck pain and neck disability among Swiss office workers: Short-term impact of COVID-19. <i>European Spine Journal</i> , 2021, 30, 1699-1707.	1.0	17
56	Anticentromere Antibody Levels and Isotypes and the Development of Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2021, 73, 2338-2347.	2.9	14
57	Estimated glomerular filtration rate is a marker of mortality in the European Scleroderma Trials and Research Group (EUSTAR) database. <i>Rheumatology</i> , 2021, 61, 213-222.	0.9	4
58	Association of Lymphangiogenic Factors With Pulmonary Arterial Hypertension in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1277-1287.	2.9	4
59	Dysregulated Expression of Arterial MicroRNAs and Their Target Gene Networks in Temporal Arteries of Treatment-Naïve Patients with Giant Cell Arteritis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6520.	1.8	9
60	Safety and efficacy of faecal microbiota transplantation by Anaerobic Cultivated Human Intestinal Microbiome (ACHIM) in patients with systemic sclerosis: study protocol for the randomised controlled phase II ReSScue trial. <i>BMJ Open</i> , 2021, 11, e048541.	0.8	7
61	<i>Staphylococcus aureus</i> impairs dermal fibroblast functions with deleterious effects on wound healing. <i>FASEB Journal</i> , 2021, 35, e21695.	0.2	13
62	Wound Image Quality From a Mobile Health Tool for Home-Based Chronic Wound Management With Real-Time Quality Feedback: Randomized Feasibility Study. <i>JMIR MHealth and UHealth</i> , 2021, 9, e26149.	1.8	13
63	An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod. <i>Arthritis Research and Therapy</i> , 2021, 23, 204.	1.6	8
64	Regulation of Monocyte Adhesion and Type I Interferon Signaling by CD52 in Patients With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1720-1730.	2.9	13
65	The burden of systemic sclerosis in Switzerland – the Swiss systemic sclerosis EUSTAR cohort. <i>Swiss Medical Weekly</i> , 2021, 151, w20528.	0.8	5
66	Engrailed 1 coordinates cytoskeletal reorganization to induce myofibroblast differentiation. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	16
67	Pulmonary Hypertension in Patients With COPD. <i>Chest</i> , 2021, 160, 678-689.	0.4	55
68	A rare disease patient-reported outcome measure: revision and validation of the German version of the Systemic Sclerosis Quality of Life Questionnaire (SScQoL) using the Rasch model. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 356.	1.2	2
69	Elevated Fibronectin Levels in Profibrotic CD14+ Monocytes and CD14+ Macrophages in Systemic Sclerosis. <i>Frontiers in Immunology</i> , 2021, 12, 642891.	2.2	20
70	Functional genomics atlas of synovial fibroblasts defining rheumatoid arthritis heritability. <i>Genome Biology</i> , 2021, 22, 247.	3.8	27
71	Patient and healthcare professional eHealth literacy and needs for systemic sclerosis support: a mixed methods study. <i>RMD Open</i> , 2021, 7, e001783.	1.8	9
72	Editorial: Precision Medicine in Chronic Inflammation. <i>Frontiers in Immunology</i> , 2021, 12, 770462.	2.2	7

#	ARTICLE	IF	CITATIONS
73	Individual functions of the histone acetyl transferases CBP and p300 in regulating the inflammatory response of synovial fibroblasts. <i>Journal of Autoimmunity</i> , 2021, 123, 102709.	3.0	4
74	Pain chronification and the important role of non-disease-specific symptoms in patients with systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2021, 23, 34.	1.6	5
75	Absenteeism and presenteeism in healthcare workers due to respiratory illness. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 268-273.	1.0	14
76	Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort. <i>European Respiratory Journal</i> , 2021, 57, 2002591.	3.1	40
77	Diarrhoea in systemic sclerosis patients as a nocebo effect of nintedanib. <i>European Respiratory Journal</i> , 2021, 57, 2003021.	3.1	3
78	On the Reliability of Suction Measurements for Skin Characterization. <i>Journal of Biomechanical Engineering</i> , 2021, 143, .	0.6	10
79	Purinergic signaling in systemic sclerosis. <i>Rheumatology</i> , 2021, , .	0.9	0
80	Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS). <i>Lancet Rheumatology</i> , The, 2021, 3, e834-e843.	2.2	42
81	The Hospital Anxiety and Depression Scale in patients with systemic sclerosis: a psychometric and factor analysis in a monocentric cohort. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 131, 34-42.	0.4	0
82	Diagnostic measures for patients with systemic sclerosis-associated myopathy. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 131, 85-93.	0.4	0
83	A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 131, 124-133.	0.4	1
84	A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 124-133.	0.4	11
85	The Hospital Anxiety and Depression Scale in patients with systemic sclerosis: a psychometric and factor analysis in a monocentric cohort. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 34-42.	0.4	15
86	Diagnostic measures for patients with systemic sclerosis-associated myopathy. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 85-93.	0.4	5
87	Prediction of organ involvement and survival in systemic sclerosis patients in the first 5 years from diagnosis. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 57-65.	1.0	8
88	Patient perception of disease burden in diffuse cutaneous systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 66-76.	1.0	7
89	Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2020, 72, 125-136.	2.9	163
90	Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020, 72, 137-149.	2.9	75

#	ARTICLE	IF	CITATIONS
91	Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. <i>Rheumatology</i> , 2020, 59, 1684-1694.	0.9	27
92	Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis. <i>Autoimmunity Reviews</i> , 2020, 19, 102458.	2.5	231
93	Heart non-specific effector CD4+ T cells protect from postinflammatory fibrosis and cardiac dysfunction in experimental autoimmune myocarditis. <i>Basic Research in Cardiology</i> , 2020, 115, 6.	2.5	17
94	Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort. <i>Rheumatology</i> , 2020, 59, 2016-2023.	0.9	14
95	Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database. <i>Autoimmunity Reviews</i> , 2020, 19, 102452.	2.5	43
96	Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 370-378.	0.5	60
97	Fibroblast growth factor receptor 3 activates a network of profibrotic signaling pathways to promote fibrosis in systemic sclerosis. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	26
98	Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. <i>Lancet Rheumatology</i> , The, 2020, 2, e743-e753.	2.2	34
99	Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 1435-1444.	0.3	104
100	Chromatin accessibility landscapes of skin cells in systemic sclerosis nominate dendritic cells in disease pathogenesis. <i>Nature Communications</i> , 2020, 11, 5843.	5.8	22
101	Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1478-1484.	0.5	46
102	Enrichment Strategy for Systemic Sclerosis Clinical Trials Targeting Skin Fibrosis: A Prospective, Multiethnic Cohort Study. <i>ACR Open Rheumatology</i> , 2020, 2, 496-502.	0.9	6
103	The AP1 Transcription Factor Fosl2 Promotes Systemic Autoimmunity and Inflammation by Repressing Treg Development. <i>Cell Reports</i> , 2020, 31, 107826.	2.9	59
104	cRel expression regulates distinct transcriptional and functional profiles driving fibroblast matrix production in systemic sclerosis. <i>Rheumatology</i> , 2020, 59, 3939-3951.	0.9	5
105	The need for a holistic approach for SSc-ILD " achievements and ambiguity in a devastating disease. <i>Respiratory Research</i> , 2020, 21, 197.	1.4	33
106	The power of the EUSTAR cohort: key findings to date and implications for management of systemic sclerosis patients. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 1065-1074.	1.3	5
107	Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database. <i>Arthritis Research and Therapy</i> , 2020, 22, 257.	1.6	20
108	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 963-974.	5.2	348



#	ARTICLE	IF	CITATIONS
109	Response to: "Correspondence on "Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension" by Ludici et al. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrheumdis-2020-219597.	0.5	0
110	Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 724-726.	0.5	51
111	Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease. <i>PLoS ONE</i> , 2020, 15, e0232978.	1.1	26
112	Serum Biomarkers for Connective Tissue and Basement Membrane Remodeling Are Associated with Vertebral Endplate Bone Marrow Lesions as Seen on MRI (Modic Changes). <i>International Journal of Molecular Sciences</i> , 2020, 21, 3791.	1.8	15
113	Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry. <i>Journal of Clinical Medicine</i> , 2020, 9, 1456.	1.0	21
114	European consensus statements for interstitial lung disease in systemic sclerosis " Authors' reply. <i>Lancet Rheumatology</i> , The, 2020, 2, e319-e320.	2.2	4
115	Validation of the suction device Nimble for the assessment of skin fibrosis in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2020, 22, 128.	1.6	7
116	Association of Anti"Topoisomerase I Antibodies of the IgM Isotype With Disease Progression in Anti"Topoisomerase I"Positive Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1897-1904.	2.9	18
117	On-site multi-component intervention to improve productivity and reduce the economic and personal burden of neck pain in Swiss office-workers (NEXpro): protocol for a cluster-randomized controlled trial. <i>BMC Musculoskeletal Disorders</i> , 2020, 21, 391.	0.8	13
118	Treatment of systemic sclerosis"associated interstitial lung disease: Lessons from clinical trials. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 61-71.	1.0	43
119	Translational engagement of lysophosphatidic acid receptor 1 in skin fibrosis: from dermal fibroblasts of patients with scleroderma to tight skin 1 mouse. <i>British Journal of Pharmacology</i> , 2020, 177, 4296-4309.	2.7	19
120	Safety and effectiveness of abatacept in systemic sclerosis: The EUSTAR experience. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1489-1493.	1.6	33
121	Predictors of progression in systemic sclerosis patients with interstitial lung disease. <i>European Respiratory Journal</i> , 2020, 55, 1902026.	3.1	134
122	The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. <i>Lancet Rheumatology</i> , The, 2020, 2, e71-e83.	2.2	182
123	Significant weight loss in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1123-1125.	0.5	11
124	COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 668-669.	0.5	107
125	Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 618-625.	0.5	71
126	Recent progress and missing gaps to achieve goal in the care of systemic sclerosis"associated interstitial lung disease. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 3-5.	1.0	9



#	ARTICLE	IF	CITATIONS
127	TGF- $\beta$ -induced epigenetic deregulation of SOCS3 facilitates STAT3 signaling to promote fibrosis. <i>Journal of Clinical Investigation</i> , 2020, 130, 2347-2363.	3.9	76
128	Long noncoding RNA H19X is a key mediator of TGF- $\beta$ -driven fibrosis. <i>Journal of Clinical Investigation</i> , 2020, 130, 4888-4905.	3.9	52
129	Activated Cardiac Fibroblasts Control Contraction of Human Fibrotic Cardiac Microtissues by a $\beta$ -Adrenoreceptor-Dependent Mechanism. <i>Cells</i> , 2020, 9, 1270.	1.8	9
130	Treatment of systemic sclerosis associated ILD: Lessons from clinical trials. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 61-71.	1.0	14
131	Evaluation of botulinum toxin A injections for the treatment of refractory chronic digital ulcers in patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 125, 154-160.	0.4	3
132	Impaired micronutrients and prealbumin in patients with established and very early systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 125, 120-126.	0.4	0
133	Visual assessment of digital ulcers in systemic sclerosis analysed by eye tracking: implications for wound assessment. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 125, 137-139.	0.4	0
134	Intravenous versus oral cyclophosphamide for lung and/or skin fibrosis in systemic sclerosis: an indirect comparison from EUSTAR and randomised controlled trials. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 125, 161-168.	0.4	5
135	Response to: "Can we further SPARkle the SPAR model?" by Kavachandha et al. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e94-e94.	0.5	0
136	Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1576-1582.	0.5	31
137	Identification and Isolation of Cardiac Fibroblasts From the Adult Mouse Heart Using Two-Color Flow Cytometry. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 105.	1.1	23
138	Clinical and Echocardiographic Associates of All-Cause Mortality and Cardiovascular Outcomes in Patients With Systemic Sclerosis. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 2273-2276.	2.3	7
139	Regulation of Fibroblast Apoptosis and Proliferation by Micro RNA $\mu$ 125b in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2019, 71, 2068-2080.	2.9	14
140	TET1 is an important transcriptional activator of TNF $\alpha$ expression in macrophages. <i>PLoS ONE</i> , 2019, 14, e0218551.	1.1	20
141	Experimental Mouse Model of Bleomycin-Induced Skin Fibrosis. <i>Current Protocols in Immunology</i> , 2019, 126, e88.	3.6	21
142	Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study). <i>Arthritis Research and Therapy</i> , 2019, 21, 217.	1.6	34
143	Fast track algorithm: How to differentiate a "scleroderma pattern" from a "non-scleroderma pattern". <i>Autoimmunity Reviews</i> , 2019, 18, 102394.	2.5	79
144	Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 1009-1017.	1.3	42

#	ARTICLE	IF	CITATIONS
145	PU.1 controls fibroblast polarization and tissue fibrosis. <i>Nature</i> , 2019, 566, 344-349.	13.7	121
146	Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II). <i>Arthritis Research and Therapy</i> , 2019, 21, 23.	1.6	33
147	Olive Leaf Extract Attenuates Inflammatory Activation and DNA Damage in Human Arterial Endothelial Cells. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 56.	1.1	83
148	Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1242-1248.	0.5	39
149	OTUD6B-AS1 Might Be a Novel Regulator of Apoptosis in Systemic Sclerosis. <i>Frontiers in Immunology</i> , 2019, 10, 1100.	2.2	22
150	Oligomeric S100A4 Is Associated With Monocyte Innate Immune Memory and Bypass of Tolerance to Subsequent Stimulation With Lipopolysaccharides. <i>Frontiers in Immunology</i> , 2019, 10, 791.	2.2	33
151	Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. <i>New England Journal of Medicine</i> , 2019, 380, 2518-2528.	13.9	1,025
152	Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features. <i>RMD Open</i> , 2019, 5, e000826.	1.8	35
153	Role of lectin pathway complement proteins and genetic variants in organ damage and disease severity of systemic sclerosis: a cross-sectional study. <i>Arthritis Research and Therapy</i> , 2019, 21, 76.	1.6	10
154	Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases—a prospective multi-centre cohort study. <i>Rheumatology</i> , 2019, 58, 1585-1596.	0.9	19
155	WNT3a and WNT5a Transported by Exosomes Activate WNT Signaling Pathways in Human Cardiac Fibroblasts. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1436.	1.8	54
156	Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 648-656.	0.5	79
157	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1553-1570.	2.9	75
158	Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 979-987.	0.5	142
159	Involvement of the myeloid cell compartment in fibrogenesis and systemic sclerosis. <i>Nature Reviews Rheumatology</i> , 2019, 15, 288-302.	3.5	48
160	Adipokine expression in systemic sclerosis lung and gastrointestinal organ involvement. <i>Cytokine</i> , 2019, 117, 41-49.	1.4	17
161	Systemic sclerosis: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000782.	1.8	91
162	THU0038â€¦INDIVIDUAL FUNCTIONS OF THE HISTONE-ACETYLTRANSFERASES CBP AND P300 IN REGULATING THE INFLAMMATORY RESPONSE OF RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
163	FRI0303â€¦THE EFFECTS OF RIOCIGUAT ON RAYNAUDâ€™S PHENOMENON AND DIGITAL ULCERS IN PATIENTS WITH DIFFUSE SYSTEMIC SCLEROSIS: RESULTS FROM THE PHASE IIB RISE-SSC STUDY. , 2019, , .		0
164	OP0185â€¦INFLAMMATION-DEPENDENT DECREASED EXPRESSION OF CD52 ON CIRCULATING CD14+ MONOCYTES FACILITATES ADHESION IN SYSTEMIC SCLEROSIS. , 2019, , .		0
165	AB0637â€¦IS VERY EARLY SYSTEMIC SCLEROSIS (SSC) A COMBINATION OF MILD AND EARLY DISEASE?. , 2019, , .		0
166	OP0245â€¦PRESERVATION OF LUNG FUNCTION OBSERVED IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL OF TOCILIZUMAB FOR THE TREATMENT OF EARLY SSC. , 2019, , .		5
167	FRI0513â€¦HISTONE-ACETYLTRANSFERASES CBP AND P300 REGULATE AUTOPHAGY AND PROTEASOMAL DEGRADATION IN SYNOVIAL FIBROBLASTS. , 2019, , .		0
168	OP0186â€¦LIN-GP38+ STROMAL CELLS ARE KEY EFFECTOR CELLS IN MYOCARDIAL FIBROSIS AND DEFECTS OF THE CONDUCTION SYSTEM. , 2019, , .		0
169	THU0345â€¦TEXTURE-BASED RADIOMICS FEATURES DISCRIMINATE DIFFERENT STAGES OF EXPERIMENTAL INTERSTITIAL LUNG DISEASE. , 2019, , .		0
170	SAT0296â€¦FAST TRACK ALGORITHM: HOW TO DIFFERENTIATE A SCLERODERMA PATTERN FROM A NON-SCLERODERMA PATTERN. , 2019, , .		3
171	OP0096â€¦DYSREGULATED BONE MARROW STROMAL CELLS IN MODIC TYPE 1 CHANGES. , 2019, , .		0
172	FRI0144â€¦JOINT-SPECIFIC RESPONSES TO TOFACITINIB AND ADALIMUMAB IN RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF DATA FROM ORAL STANDARD AND ORAL STRATEGY. , 2019, , .		0
173	OP0068â€¦ABATACEPT IN EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSISâ€” RESULTS OF A PHASE 2 INVESTIGATOR-INITIATED, MULTICENTER, DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL. , 2019, , .		1
174	FRI0325â€¦IDENTIFYING SYSTEMIC SCLEROSIS PATIENTS AT RISK OF PROGRESSIVE LUNG FIBROSIS â€” A EUSTAR DATABASE ANALYSIS. , 2019, , .		0
175	OP0239â€¦PROGRESSIVE LUNG FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE IN THE EUSTAR DATABASE. , 2019, , .		1
176	SAT0001â€¦FOSL-2 IS A REPRESSOR OF FOXP3 EXPRESSION DURING TREG DEVELOPMENT AND CONTROLS AUTOIMMUNITY. , 2019, , .		0
177	OP0064â€¦EVIDENCE-BASED CONSENSUS RECOMMENDATIONS FOR THE IDENTIFICATION AND MANAGEMENT OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS. , 2019, , .		4
178	OP0242â€¦SAFETY PROFILE OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE AND IDIOPATHIC PULMONARY FIBROSIS. , 2019, , .		0
179	OP0017â€¦NINTEDANIB REDUCED DECLINE IN FORCED VITAL CAPACITY ACROSS SUBGROUPS OF PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: DATA FROM THE SENSICIS TRIAL. , 2019, , .		0
180	SAT0273â€¦PREDICTIVE VALUE OF THE REVISED EUROPEAN SCLERODERMA TRIALS AND RESEARCH GROUP ACTIVITY INDEX (EUSTAR-AI). , 2019, , .		0

#	ARTICLE	IF	CITATIONS
181	FRI0301â€¦GASTROINTESTINAL ADVERSE EVENTS IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) TREATED WITH NINTEDANIB: DATA FROM THE SENSICIS TRIAL. , 2019, , .		0
182	OP0290â€¦HOTAIR IS INVOLVED IN JOINT PATTERNING BY REGULATING FGFR2, BMP2 AND WNT PATHWAYS. , 2019, , .		1
183	SAT0055â€¦JOINT SPECIFIC TNF RESPONSE OF SYNOVIAL FIBROBLASTS IN RHEUMATOID ARTHRITIS. , 2019, , .		0
184	THU0356â€¦STAPHYLOCOCCUS AUREUS REGULATES FIBROBLAST FUNCTIONS â€“ IMPLICATIONS FOR TISSUE REPAIR IN CHRONIC DIGITAL ULCERS IN SYSTEMIC SCLEROSIS. , 2019, , .		0
185	SAT0254â€¦VASODILATOR THERAPY IN THE LONG TERM PREVENTION OF MYOCARDIAL MANIFESTATIONS IN SYSTEMIC SCLEROSIS (SSC): RESULTS FROM DESSCIPHER INCEPTION COHORT STUDY. , 2019, , .		0
186	THU0006â€¦PROINFLAMMATORY RESPONSES IN THE JAK-STAT PATHWAY IN SYNOVIAL FIBROBLASTS ARE STIMULUS-SPECIFIC AND ONLY PARTIALLY INHIBITED BY THERAPEUTIC DOSES OF TOFACITINIB. , 2019, , .		0
187	OP0221â€¦OLIGOMERIC S100A4 INDUCES MONOCYTE INNATE IMMUNE MEMORY. , 2019, , .		0
188	OP0184â€¦PROFIBROTIC LNCRNA H19X: UNRAVELLING THE EFFECTS ON CHROMATIN REMODELING IN SYSTEMIC SCLEROSIS FIBROBLASTS. , 2019, , .		0
189	SAT0264â€¦GAZE PATTERN ANALYSIS IN THE ASSESSMENT OF DIGITAL ULCERS IN PATIENTS WITH SYSTEMIC SCLEROSIS. , 2019, , .		0
190	SAT0234â€¦RNA SEQUENCING IDENTIFIES AN IGA VASCULITIS ASSOCIATED SERUM MICRORNA SIGNATURE, DISCRIMINATING PATIENTS WITH IGA VASCULITIS FROM AGE- AND SEX-MATCHED HEALTHY SUBJECTS. , 2019, , .		0
191	OP0183â€¦EFFICACY AND SAFETY OF RIOCIQUAT IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS AND INTERSTITIAL LUNG DISEASE (SSC-ILD): RESULTS FROM THE PHASE IIB RISE-SSC STUDY. , 2019, , .		2
192	OP0065â€¦THE VERY EARLY DIAGNOSIS OF SYSTEMIC SCLEROSIS (VEDOSS) PROJECT: PREDICTORS TO DEVELOP DEFINITE DISEASE FROM AN INTERNATIONAL MULTICENTRE STUDY. , 2019, , .		1
193	THU0343â€¦PU.1 INHIBITOR DB1976 CONTROLS FIBROBLAST POLARIZATION IN SYSTEMIC SCLEROSIS AND LEADS TO REGRESSION OF FIBROSIS IN DIFFERENT MODELS OF ORGAN FIBROSIS. , 2019, , .		0
194	Might Nailfold Capillaroscopy Be a â€œProxyâ€•for Lung Involvement in Connective Tissue Diseases?. Journal of Rheumatology, 2019, 46, 1061-1063.	1.0	13
195	Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual. Annals of the Rheumatic Diseases, 2019, 78, 1681-1685.	0.5	13
196	18F-AzaFol for Detection of Folate Receptor- $\hat{1}^2$ Positive Macrophages in Experimental Interstitial Lung Diseaseâ€”A Proof-of-Concept Study. Frontiers in Immunology, 2019, 10, 2724.	2.2	27
197	Response to: â€˜Will SPAR be useful in the usual patients with scleroderma?â€™ <sup>TM</sup> by Chattopadhyay <i>et al</i>. Annals of the Rheumatic Diseases, 2019, 78, e126-e126.	0.5	0
198	Visualisation of interstitial lung disease by molecular imaging of integrin $\hat{1}\pm\hat{v}^23$ and somatostatin receptor 2. Annals of the Rheumatic Diseases, 2019, 78, 218-227.	0.5	24

#	ARTICLE	IF	CITATIONS
199	Reduced Right Ventricular Output Reserve in Patients With Systemic Sclerosis and Mildly Elevated Pulmonary Artery Pressure. <i>Arthritis and Rheumatology</i> , 2019, 71, 805-816.	2.9	25
200	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. <i>Arthritis and Rheumatology</i> , 2019, 71, 964-971.	2.9	41
201	<sup>18</sup> F-fluorodeoxyglucose positron-emission tomography/CT and lung involvement in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 577-578.	0.5	17
202	Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. <i>Autoimmunity Reviews</i> , 2019, 18, 93-106.	2.5	101
203	Increased expression of the TNF superfamily member LIGHT/TNFSF14 and its receptors (HVEM and LT $\alpha$ ) in patients with systemic sclerosis. <i>Rheumatology</i> , 2019, 58, 502-510.	0.9	7
204	Abnormal esophageal motility during a solid test meal in systemic sclerosis – detection even in very early disease and association with disease progression. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13480.	1.6	13
205	Practical suggestions on intravenous iloprost in Raynaud’s phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 686-693.	1.6	34
206	Lung function preservation in a phase 3 trial of tocilizumab (TCZ) in systemic sclerosis (SSc)., 2019, , .		2
207	Vascular Mechanisms of Systemic Sclerosis. , 2019, , 27-37.		4
208	Does angiotensin and endothelin receptor blockade have an impact on lung function? An analysis from the EUSTAR database. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 119, 154-155.	0.4	1
209	Cardiac manifestation of polyarteritis nodosa. <i>European Heart Journal</i> , 2018, 39, 2603-2603.	1.0	4
210	Poly(ADP-ribose) polymerase-1 regulates fibroblast activation in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 744-751.	0.5	36
211	Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2018, 57, 813-817.	0.9	21
212	Antisense Long Non-Coding RNAs Are Deregulated in Skin Tissue of Patients with Systemic Sclerosis. <i>Journal of Investigative Dermatology</i> , 2018, 138, 826-835.	0.3	37
213	Location-specific mechanical response and morphology of facial soft tissues. <i>Journal of the Mechanical Behavior of Biomedical Materials</i> , 2018, 78, 108-115.	1.5	22
214	Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 459-459.	0.5	33
215	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 563-570.	0.5	50
216	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. <i>Rheumatology</i> , 2018, 57, 370-381.	0.9	53

#	ARTICLE	IF	CITATIONS
217	Multidimensional fatigue in pulmonary hypertension: prevalence, severity and predictors. <i>ERJ Open Research</i> , 2018, 4, 00079-2017.	1.1	10
218	Reliability of simple capillaroscopic definitions in describing capillary morphology in rheumatic diseases. <i>Rheumatology</i> , 2018, 57, 757-759.	0.9	60
219	Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis. <i>European Respiratory Journal</i> , 2018, 51, 1701197.	3.1	76
220	The emerging application of semi-quantitative and quantitative capillaroscopy in systemic sclerosis. <i>Microvascular Research</i> , 2018, 118, 113-120.	1.1	23
221	Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 626-628.	0.5	12
222	Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group. <i>Rheumatology</i> , 2018, 57, 441-450.	0.9	60
223	Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 128-132.	0.5	20
224	The histone demethylase Jumonji domain-containing protein 3 (JMJD3) regulates fibroblast activation in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 150-158.	0.5	51
225	Polyarteritis nodosa. <i>Rheumatology</i> , 2018, 57, 670-670.	0.9	4
226	Nodular Regenerative Hyperplasia of the Liver: A Rare Vascular Complication in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2018, 45, 103-106.	1.0	13
227	Review: Defining a Unified Vascular Phenotype in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2018, 70, 162-170.	2.9	48
228	The impact of slice-reduced computed tomography on histogram-based densitometry assessment of lung fibrosis in patients with systemic sclerosis. <i>Journal of Thoracic Disease</i> , 2018, 10, 2142-2152.	0.6	24
229	Prospective evaluation of the capillaroscopic skin ulcer risk index in systemic sclerosis patients in clinical practice: a longitudinal, multicentre study. <i>Arthritis Research and Therapy</i> , 2018, 20, 239.	1.6	4
230	European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis. <i>Rheumatology</i> , 2018, 58, 254-259.	0.9	11
231	Gouty arthritis: Can we avoid unnecessary dual-energy CT examinations using prior radiographs?. <i>PLoS ONE</i> , 2018, 13, e0200473.	1.1	4
232	Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. <i>International Journal of Cardiology</i> , 2018, 272, 37-45.	0.8	56
233	Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study. <i>Arthritis and Rheumatology</i> , 2018, 70, 1829-1834.	2.9	15
234	Haematopoietic stem cell transplantation in systemic sclerosis. <i>RMD Open</i> , 2018, 4, e000533.	1.8	31



#	ARTICLE	IF	CITATIONS
235	Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. <i>Arthritis Research and Therapy</i> , 2018, 20, 17.	1.6	75
236	Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1634-1643.	2.9	74
237	Evaluation of 99mTc-rhAnnexin V-128 SPECT/CT as a diagnostic tool for early stages of interstitial lung disease associated with systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2018, 20, 183.	1.6	21
238	The tyrosine phosphatase SHP2 controls TGF $\beta$ <sup>2</sup> -induced STAT3 signaling to regulate fibroblast activation and fibrosis. <i>Nature Communications</i> , 2018, 9, 3259.	5.8	89
239	A novel ultra-light suction device for mechanical characterization of skin. <i>PLoS ONE</i> , 2018, 13, e0201440.	1.1	31
240	Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1326-1332.	0.5	100
241	Gender differences in early systemic sclerosis patients: a report from the EULAR scleroderma trials and research group (EUSTAR) database. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 68-75.	0.4	3
242	Transforming growth factor- $\beta$ <sup>2</sup> -dependent Wnt secretion controls myofibroblast formation and myocardial fibrosis progression in experimental autoimmune myocarditis. <i>European Heart Journal</i> , 2017, 38, ehw116.	1.0	134
243	Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening. <i>Journal of Rheumatology</i> , 2017, 44, 639-647.	1.0	93
244	The transcription factor GLI2 as a downstream mediator of transforming growth factor- $\beta$ <sup>2</sup> -induced fibroblast activation in SSc. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 756-764.	0.5	53
245	Composition of TWIST1 dimers regulates fibroblast activation and tissue fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 244-251.	0.5	28
246	The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 270-276.	0.5	132
247	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1207-1218.	0.5	107
248	JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1467-1475.	0.5	41
249	Use of biologics and other novel therapies for the treatment of systemic sclerosis. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 469-482.	1.3	29
250	Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1327-1339.	0.5	794
251	Points to consider when doing a trial primarily involving the heart. <i>Rheumatology</i> , 2017, 56, v12-v16.	0.9	6
252	Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis. <i>Nature Communications</i> , 2017, 8, 1130.	5.8	245



#	ARTICLE	IF	CITATIONS
253	Muscle involvement in systemic sclerosis: points to consider in clinical trials. <i>Rheumatology</i> , 2017, 56, v38-v44.	0.9	27
254	Mapping and predicting mortality from systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1897-1905.	0.5	410
255	Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells. <i>Nature Medicine</i> , 2017, 23, 938-944.	15.2	223
256	Pharyngeal swallowing and oesophageal motility during a solid meal test: a prospective study in healthy volunteers and patients with major motility disorders. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 644-653.	3.7	65
257	The epigenetic architecture at gene promoters determines cell type-specific LPS tolerance. <i>Journal of Autoimmunity</i> , 2017, 83, 122-133.	3.0	25
258	Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1941-1948.	0.5	149
259	Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. <i>European Respiratory Journal</i> , 2017, 50, 1700740.	3.1	489
260	05.11 Antisense long noncoding rnas are deregulated in skin tissue of ssc patients. , 2017, , .		0
261	Tie2 as a novel key factor of microangiopathy in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2017, 19, 105.	1.6	25
262	RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis. <i>Respiratory Medicine</i> , 2017, 122, S14-S17.	1.3	29
263	Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2017, 69, 257-267.	2.9	62
264	Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 11-18.	1.0	321
265	What have multicentre registries across the world taught us about the disease features of systemic sclerosis?. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 169-182.	1.0	18
266	Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) Definition. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 115-120.	1.0	62
267	Innovative Approaches to Clinical Trials in Systemic Sclerosis. , 2017, , 649-656.		0
268	Incidence of new pulmonary hypertension and determining factors during follow-up of patients with systemic sclerosis after negative right heart catheterisation. , 2017, , .		0
269	Clinical determinants of elevated systolic pulmonary artery pressure measured by transthoracic Doppler echocardiography in early systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 114-121.	0.4	1
270	Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCISâ„†). <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 75-81.	0.4	39

#	ARTICLE	IF	CITATIONS
271	Sirt1 regulates canonical TGF- $\beta$ 2 signalling to control fibroblast activation and tissue fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 226-233.	0.5	115
272	A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 163-169.	0.5	82
273	Progress and Priorities in Systemic Sclerosis: The Next 10 Years – Report from the World Scleroderma Foundation. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 7-9.	1.0	3
274	Effect of endothelin-1 receptor antagonists on skin fibrosis in scleroderma patients from the EUSTAR database. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 220-225.	1.0	3
275	Rapid Growth of Lung Nodules due to Combined Pulmonary Vasculitis, Silicoanthracosis, and Chondrocalcinosis. <i>Canadian Respiratory Journal</i> , 2016, 2016, 1-4.	0.8	2
276	Emerging strategies for treatment of systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 186-193.	1.0	41
277	Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1743-1748.	0.5	68
278	Exercise pulmonary haemodynamics predict outcome in patients with systemic sclerosis. <i>European Respiratory Journal</i> , 2016, 48, 1658-1667.	3.1	63
279	Treatment of systemic sclerosis: is there any hope for the future?: Table 1. <i>RMD Open</i> , 2016, 2, e000260.	1.8	19
280	Efficient therapy of ischaemic lesions with VEGF <sub>121</sub> -fibrin in an animal model of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1399-1406.	0.5	3
281	Tocilizumab for systemic sclerosis: implications for future trials. <i>Lancet, The</i> , 2016, 387, 2580-2581.	6.3	13
282	Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study. <i>Arthritis and Rheumatology</i> , 2016, 68, 2527-2539.	2.9	122
283	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2016, 68, 167-178.	1.5	13
284	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2016, 68, 299-311.	2.9	110
285	Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 303-310.	0.5	45
286	Tribbles homologue 3 stimulates canonical TGF- $\beta$ 2 signalling to regulate fibroblast activation and tissue fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 609-616.	0.5	38
287	Impaired quality of life in systemic sclerosis and patient perception of the disease: A large international survey. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 115-123.	1.6	84
288	An EULAR study group pilot study on reliability of simple capillaroscopic definitions to describe capillary morphology in rheumatic diseases. <i>Rheumatology</i> , 2016, 55, 883-890.	0.9	121

#	ARTICLE	IF	CITATIONS
289	Systemic sclerosis and localized scleroderma – current concepts and novel targets for therapy. <i>Seminars in Immunopathology</i> , 2016, 38, 87-95.	2.8	79
290	Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1285-1292.	0.5	56
291	Activating transcription factor 3 regulates canonical TGF $\beta$ 2 signalling in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 586-592.	0.5	28
292	Type 2 innate lymphoid cell counts are increased in patients with systemic sclerosis and correlate with the extent of fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 623-626.	0.5	78
293	Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 883-890.	0.5	154
294	Incidence and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. <i>PLoS ONE</i> , 2016, 11, e0163894.	1.1	158
295	Safety and efficacy of extracorporeal shock wave therapy (ESWT) in calcinosis cutis associated with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 177-180.	0.4	7
296	Effects of rituximab in connective tissue disorders related interstitial lung disease. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 181-185.	0.4	20
297	Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2015, 67, 3256-3261.	2.9	157
298	Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias. <i>PLoS ONE</i> , 2015, 10, e0141911.	1.1	80
299	Performance of the new ACR/EULAR classification criteria for systemic sclerosis in clinical practice. <i>Rheumatology</i> , 2015, 54, 1454-1458.	0.9	67
300	Inhibition of casein kinase II reduces TGF $\beta$ 2 induced fibroblast activation and ameliorates experimental fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 936-943.	0.5	45
301	Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population. <i>Rheumatology</i> , 2015, 54, 1262-1269.	0.9	25
302	Advances in cohort enrichment shape future of trial design. <i>Nature Reviews Rheumatology</i> , 2015, 11, 72-74.	3.5	19
303	Management of Scleroderma-Associated Pulmonary Involvement. <i>Current Treatment Options in Rheumatology</i> , 2015, 1, 51-67.	0.6	0
304	Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGF $\beta$ 2 signalling. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1408-1416.	0.5	92
305	Orphan nuclear receptor NR4A1 regulates transforming growth factor- $\beta$ 2 signaling and fibrosis. <i>Nature Medicine</i> , 2015, 21, 150-158.	15.2	267
306	Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards. <i>Rheumatology</i> , 2015, 54, 144-151.	0.9	30

#	ARTICLE	IF	CITATIONS
307	Cardiomyopathy in Murine Models of Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2015, 67, 508-516.	2.9	39
308	Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1124-1131.	0.5	96
309	Systemic sclerosis. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15002.	18.1	587
310	Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1621-1625.	0.5	60
311	A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study. <i>Microvascular Research</i> , 2015, 102, 19-24.	1.1	13
312	Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1317-1324.	0.5	28
313	Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1188-1194.	0.5	340
314	S100A4 amplifies TGF- $\beta$ <sup>2</sup> -induced fibroblast activation in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1748-1755.	0.5	52
315	Vitamin D receptor regulates TGF- $\beta$ <sup>2</sup> signalling in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e20-e20.	0.5	111
316	Outcome Measures for Clinical Trials in Interstitial Lung Diseases. <i>Current Respiratory Medicine Reviews</i> , 2015, 11, 163-174.	0.1	29
317	Autopsy versus clinical findings in patients with systemic sclerosis in a case series from patients of the EUSTAR database. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S75-9.	0.4	13
318	Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1880-1887.	0.5	69
319	Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study. <i>Arthritis Research and Therapy</i> , 2014, 16, 493.	1.6	44
320	Oxidative DNA damage induces the ATM-mediated transcriptional suppression of the Wnt inhibitor WIF-1 in systemic sclerosis and fibrosis. <i>Science Signaling</i> , 2014, 7, ra84.	1.6	84
321	Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. <i>Thorax</i> , 2014, 69, 436-444.	2.7	100
322	Prevalence, Correlates and Outcomes of Gastric Antral Vascular Ectasia in Systemic Sclerosis: A EUSTAR Case-control Study. <i>Journal of Rheumatology</i> , 2014, 41, 99-105.	1.0	73
323	The Nuclear Receptor Constitutive Androstane Receptor/NR1I3 Enhances the Profibrotic Effects of Transforming Growth Factor $\beta$ <sup>2</sup> and Contributes to the Development of Experimental Dermal Fibrosis. <i>Arthritis and Rheumatology</i> , 2014, 66, 3140-3150.	2.9	13
324	Nailfold capillary abnormalities in erectile dysfunction of systemic sclerosis: a EUSTAR group analysis. <i>Rheumatology</i> , 2014, 53, 639-643.	0.9	8

#	ARTICLE	IF	CITATIONS
325	Screening for interstitial lung disease in systemic sclerosis: performance of high-resolution CT with limited number of slices: a prospective study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2069-2073.	0.5	63
326	Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1340-1349.	0.5	633
327	Cardiac arrhythmias and conduction defects in systemic sclerosis. <i>Rheumatology</i> , 2014, 53, 1172-1177.	0.9	83
328	Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2087-2093.	0.5	168
329	Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1264-1268.	0.5	32
330	The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1232-1239.	0.5	166
331	Expert consensus for performing right heart catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 191-197.	0.5	41
332	Inactivation of evenness interrupted (EVI) reduces experimental fibrosis by combined inhibition of canonical and non-canonical Wnt signalling. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 624-627.	0.5	26
333	Personalized Medicine in Systemic Sclerosis: Facts and Promises. <i>Current Rheumatology Reports</i> , 2014, 16, 425.	2.1	17
334	Heat shock protein 90 (Hsp90) inhibition targets canonical TGF- $\beta$ 2 signalling to prevent fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1215-1222.	0.5	78
335	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 706-714.	2.4	52
336	A3.19â€¦mIR-193B induces UPA in SSC and contributes to the proliferative vasculopathy via uPAR independent pathways. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A49.2-A49.	0.5	0
337	Novel Aspects in the Pathophysiology of Peripheral Vasculopathy in Systemic Sclerosis. <i>Current Rheumatology Reviews</i> , 2014, 9, 237-244.	0.4	11
338	Visual problem and low back pain as initial manifestation of multiple myeloma complicating pre-existing systemic sclerosis. <i>Journal of the College of Physicians and Surgeons-Pakistan: JCPSP</i> , 2014, 24 Suppl 1, S29-31.	0.2	2
339	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. <i>Arthritis and Rheumatism</i> , 2013, 65, 2737-2747.	6.7	2,359
340	Recommendations for Screening and Detection of Connective Tissue Disease-associated Pulmonary Arterial Hypertension. <i>Arthritis and Rheumatism</i> , 2013, 65, 3194-3201.	6.7	175
341	Treating skin and lung fibrosis in systemic sclerosis: a future filled with promise?. <i>Current Opinion in Pharmacology</i> , 2013, 13, 455-462.	1.7	16
342	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1747-1755.	0.5	1,705

#	ARTICLE	IF	CITATIONS
343	Activation of pregnane X receptor inhibits experimental dermal fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 621-625.	0.5	22
344	The Fra-2 transgenic mouse model of systemic sclerosis. <i>Vascular Pharmacology</i> , 2013, 58, 194-201.	1.0	54
345	Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry. <i>International Journal of Cardiology</i> , 2013, 168, 871-880.	0.8	357
346	Nailfold capillaroscopy in systemic sclerosis: Data from the EULAR scleroderma trials and research (EUSTAR) database. <i>Microvascular Research</i> , 2013, 89, 122-128.	1.1	101
347	Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 614-620.	0.5	93
348	Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical Wnt signalling. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1575-1580.	0.5	69
349	Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1255-1258.	0.5	98
350	Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 2039-2046.	0.5	20
351	Preclinical and translational research to discover potentially effective antifibrotic therapies in systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 2013, 25, 679-685.	2.0	15
352	Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1217-1220.	0.5	160
353	Autophagy regulates TNF $\alpha$ -mediated joint destruction in experimental arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 761-768.	0.5	249
354	A8.3 $\alpha$ Deficit of S100A4 Prevents Joint Destruction and Systemic Bone Loss in hTNF $\alpha$ Mouse Model. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A58.1-A58.	0.5	0
355	Skin lesions in anti-Pm-Scl-70 positive systemic sclerosis-dermatomyositis overlap syndrome improve during local PUVA phototherapy. <i>European Journal of Dermatology</i> , 2013, 23, 730-731.	0.3	6
356	The 12/15-lipoxygenase pathway counteracts fibroblast activation and experimental fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1081-1087.	0.5	35
357	International Classification of Functioning, Disability and Health Core Set construction in systemic sclerosis and other rheumatic diseases: a EUSTAR initiative. <i>Rheumatology</i> , 2012, 51, 2170-2176.	0.9	23
358	Innovative antifibrotic therapies in systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 2012, 24, 274-280.	2.0	48
359	Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 737-745.	0.5	53
360	Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1355-1360.	0.5	275



#	ARTICLE	IF	CITATIONS
361	Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 785-789.	0.5	73
362	Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1019-1026.	0.5	74
363	Pomalidomide is effective for prevention and treatment of experimental skin fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1895-1899.	0.5	31
364	Inactivation of fatty acid amide hydrolase exacerbates experimental fibrosis by enhanced endocannabinoid-mediated activation of CB1. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 2051-2054.	0.5	26
365	Screening for interstitial lung disease in systemic sclerosis: the diagnostic accuracy of HRCT image series with high increment and reduced number of slices. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 549-552.	0.5	36
366	Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease. <i>Blood</i> , 2012, 120, 2909-2917.	0.6	53
367	Inhibition of sumoylation prevents experimental fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1904-1908.	0.5	28
368	Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1382-1387.	0.5	93
369	Adiponectin relation to skin changes and dyslipidemia in systemic sclerosis. <i>Cytokine</i> , 2012, 58, 165-168.	1.4	29
370	JAK $\epsilon$ 2 as a novel mediator of the profibrotic effects of transforming growth factor $\beta$ 2 in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2012, 64, 3006-3015.	6.7	115
371	Is There Evidence for Vasculitis in Systemic Sclerosis?. <i>Current Rheumatology Reports</i> , 2012, 14, 516-525.	2.1	15
372	Biomarkers of Fibrosis. , 2012, , 283-290.		0
373	Combined Inhibition of c-Abl and PDGF Receptors for Prevention and Treatment of Murine Sclerodermatous Chronic Graft-versus-Host Disease. <i>American Journal of Pathology</i> , 2012, 181, 1672-1680.	1.9	28
374	Activation of canonical Wnt signalling is required for TGF- $\beta$ 2-mediated fibrosis. <i>Nature Communications</i> , 2012, 3, 735.	5.8	649
375	International cohort study of 73 anti-Ku-positive patients: association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis. <i>Arthritis Research and Therapy</i> , 2012, 14, R2.	1.6	19
376	Erectile dysfunction is frequent in systemic sclerosis and associated with severe disease: a study of the EULAR Scleroderma Trial and Research group. <i>Arthritis Research and Therapy</i> , 2012, 14, R37.	1.6	41
377	Inhibition of activator protein 1 signaling abrogates transforming growth factor $\beta$ 2-mediated activation of fibroblasts and prevents experimental fibrosis. <i>Arthritis and Rheumatism</i> , 2012, 64, 1642-1652.	6.7	81
378	Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2012, 64, 2724-2733.	6.7	133



#	ARTICLE	IF	CITATIONS
379	β2-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 761-767.	0.5	174
380	Molecular targets for therapy in systemic sclerosis. <i>Fibrogenesis and Tissue Repair</i> , 2012, 5, S19.	3.4	15
381	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. <i>Arthritis Care and Research</i> , 2012, 64, 351-357.	1.5	49
382	Role of MicroRNAs in Fibrosis. <i>Open Rheumatology Journal</i> , 2012, 6, 130-139.	0.1	144
383	Pulmonary arterial hypertension in connective tissue diseases. , 2012, , 42-57.		0
384	EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1178-1182.	0.5	30
385	Inhibition of glycogen synthase kinase 3 $\alpha$ induces dermal fibrosis by activation of the canonical Wnt pathway. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2191-2198.	0.5	96
386	Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed. <i>Arthritis Research and Therapy</i> , 2011, 13, 114.	1.6	8
387	Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1304-1310.	0.5	116
388	Epigenetic modifications: novel therapeutic strategies for systemic sclerosis?. <i>Expert Review of Clinical Immunology</i> , 2011, 7, 475-480.	1.3	27
389	Treatment of pulmonary arterial hypertension (PAH): Updated Recommendations of the Cologne Consensus Conference 2011. <i>International Journal of Cardiology</i> , 2011, 154, S20-S33.	0.8	46
390	Systemic Sclerosis 2011. <i>International Journal of Rheumatology</i> , 2011, 2011, 1-2.	0.9	0
391	Microparticles stimulate angiogenesis by inducing ELR+ CXC-chemokines in synovial fibroblasts. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 756-762.	1.6	45
392	Emerging targeted therapies in scleroderma lung and skin fibrosis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 843-858.	1.4	11
393	Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: From Animal Models to Clinical Trials. <i>Current Rheumatology Reports</i> , 2011, 13, 21-27.	2.1	41
394	Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2011, 63, 800-809.	6.7	73
395	Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. <i>Arthritis and Rheumatism</i> , 2011, 63, 1396-1404.	6.7	107
396	Induction of apoptosis in circulating angiogenic cells by microparticles. <i>Arthritis and Rheumatism</i> , 2011, 63, 2067-2077.	6.7	36

#	ARTICLE	IF	CITATIONS
397	Analysis of the Validation Status of Quality of Life and Functional Disability Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis: Results of a Systematic Literature Analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (EPOSS). <i>Journal of Rheumatology</i> , 2011, 38, 2419-2427.	1.0	4
398	The transcription factor JunD mediates transforming growth factor $\beta$ -induced fibroblast activation and fibrosis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1320-1326.	0.5	59
399	Concepts of functioning and health important to people with systemic sclerosis: a qualitative study in four European countries. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1074-1079.	0.5	59
400	Platelet-derived serotonin links vascular disease and tissue fibrosis. <i>Journal of Experimental Medicine</i> , 2011, 208, 961-972.	4.2	222
401	Dysbalance of angiogenic and angiostatic mediators in patients with mixed connective tissue disease. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1197-1202.	0.5	21
402	Is there a role for TNF $\alpha$ antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, S40-5.	0.4	57
403	Promising Anti-Fibrotic Approaches for Future Treatment of Systemic Sclerosis. <i>Current Rheumatology Reviews</i> , 2010, 6, 305-308.	0.4	0
404	Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design. <i>Current Rheumatology Reviews</i> , 2010, 6, 138-144.	0.4	28
405	The transcription factor Fra $\alpha$ 2 regulates the production of extracellular matrix in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2010, 62, 280-290.	6.7	97
406	Evaluation of the efficacy and safety of tergruride in patients with fibromyalgia syndrome: Results of a twelve-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. <i>Arthritis and Rheumatism</i> , 2010, 62, 291-300.	6.7	24
407	Decreased lymphatic vessel counts in patients with systemic sclerosis: Association with fingertip ulcers. <i>Arthritis and Rheumatism</i> , 2010, 62, 1513-1522.	6.7	22
408	MicroRNA $\alpha$ 29, a key regulator of collagen expression in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2010, 62, 1733-1743.	6.7	470
409	Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis. <i>Arthritis and Rheumatism</i> , 2010, 62, 3467-3476.	6.7	67
410	Animal models of systemic sclerosis: Prospects and limitations. <i>Arthritis and Rheumatism</i> , 2010, 62, 2831-2844.	6.7	135
411	Promoter hypermethylation of the anti-fibrotic gene socs-3 by TGF $\beta$ as novel mechanism in the pathogenesis of SSc. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, A26-A26.	0.5	0
412	Activation of Hedgehog signalling plays a crucial role in the pathogenesis of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, A27-A27.	0.5	0
413	Potential adipokine involvement in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, A25-A25.	0.5	0
414	Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1360-1363.	0.5	34

#	ARTICLE	IF	CITATIONS
415	5-HT release from platelets and activation of 5-HT <sub>2B</sub> play a crucial role for development of fibrosis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, A26-A27.	0.5	1
416	Vascular Disease in Systemic Sclerosis. <i>International Journal of Rheumatology</i> , 2010, 2010, 1-2.	0.9	4
417	Echocardiography as an Outcome Measure in Scleroderma-related Pulmonary Arterial Hypertension: A Systematic Literature Analysis by the EPOSS Group. <i>Journal of Rheumatology</i> , 2010, 37, 105-115.	1.0	37
418	Microparticles and their roles in inflammatory arthritides. <i>Nature Reviews Rheumatology</i> , 2010, 6, 385-386.	3.5	27
419	Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1809-1815.	0.5	1,017
420	Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?. <i>Swiss Medical Weekly</i> , 2010, 140, w13050.	0.8	26
421	Interactions between rheumatologists and cardio-/pulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, S47-52.	0.4	7
422	Measures of Response in Clinical Trials of Systemic Sclerosis: The Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (EPOSS). <i>Journal of Rheumatology</i> , 2009, 36, 2356-2361.	1.0	43
423	Stiff skin syndrome: evidence for an inflammation-independent fibrosis?. <i>Rheumatology</i> , 2009, 48, 849-852.	0.9	15
424	Transcription Factor Fos-Related Antigen-2 Induces Progressive Peripheral Vasculopathy in Mice Closely Resembling Human Systemic Sclerosis. <i>Circulation</i> , 2009, 120, 2367-2376.	1.6	105
425	Lack of inhibitory effects of the anti-fibrotic drug imatinib on endothelial cell functions <i>in vitro</i> and <i>in vivo</i> . <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 4185-4191.	1.6	11
426	Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. <i>Arthritis and Rheumatism</i> , 2009, 60, 219-224.	6.7	187
427	Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: What functional autoimmunity could learn from receptor biology. <i>Arthritis and Rheumatism</i> , 2009, 60, 907-911.	6.7	35
428	The cannabinoid receptor CB <sub>2</sub> exerts antifibrotic effects in experimental dermal fibrosis. <i>Arthritis and Rheumatism</i> , 2009, 60, 1129-1136.	6.7	106
429	Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2009, 60, 1519-1529.	6.7	100
430	Endothelial progenitor cells: Novel players in the pathogenesis of rheumatic diseases. <i>Arthritis and Rheumatism</i> , 2009, 60, 3168-3179.	6.7	39
431	Inhibitor of DNA binding/differentiation 2 induced by hypoxia promotes synovial fibroblast-dependent osteoclastogenesis. <i>Arthritis and Rheumatism</i> , 2009, 60, 3663-3675.	6.7	14
432	Mechanisms of vascular damage in systemic sclerosis. <i>Autoimmunity</i> , 2009, 42, 587-595.	1.2	65

#	ARTICLE	IF	CITATIONS
433	Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2009, 11, 220.	1.6	99
434	Animal Models of Scleroderma: From Cellular and Molecular Mechanisms to Novel Antifibrotic Strategies. , 2009, , 57-75.		1
435	Src kinases in systemic sclerosis: Central roles in fibroblast activation and in skin fibrosis. <i>Arthritis and Rheumatism</i> , 2008, 58, 1475-1484.	6.7	111
436	The controversial role of tumor necrosis factor $\hat{\pm}$ in fibrotic diseases. <i>Arthritis and Rheumatism</i> , 2008, 58, 2228-2235.	6.7	96
437	Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. <i>Arthritis and Rheumatism</i> , 2008, 58, 2553-2564.	6.7	102
438	Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease. <i>Arthritis and Rheumatism</i> , 2008, 58, 2538-2542.	6.7	43
439	Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: A Delphi consensus study with cluster analysis. <i>Arthritis and Rheumatism</i> , 2008, 59, 867-875.	6.7	56
440	The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2008, 58, 2845-2853.	6.7	91
441	Novel Treatment Approaches to Fibrosis in Scleroderma. <i>Rheumatic Disease Clinics of North America</i> , 2008, 34, 145-159.	0.8	16
442	Dual inhibition of c-Kit and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. <i>FASEB Journal</i> , 2008, 22, 2214-2222.	0.2	179
443	Diagnosis of pulmonary arterial hypertension in a patient with systemic sclerosis. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 160-164.	3.2	2
444	Cardiotoxicity of imatinib mesylate: an extremely rare phenomenon or a major side effect?. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 836-836.	0.5	15
445	Cells of the synovium in rheumatoid arthritis. Synovial fibroblasts. <i>Arthritis Research and Therapy</i> , 2007, 9, 223.	1.6	193
446	Regulation of eicosanoid production in peripheral blood mononuclear cells from patients with systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2007, 9, P13.	1.6	0
447	How does endothelial cell injury start? The role of endothelin in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2007, 9, S2.	1.6	132
448	Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2007, 9, S3.	1.6	128
449	Mechanisms of Disease: leukotrienes and lipoxins in scleroderma lung disease—insights and potential therapeutic implications. <i>Nature Clinical Practice Rheumatology</i> , 2007, 3, 43-51.	3.2	31
450	Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. <i>Arthritis and Rheumatism</i> , 2007, 56, 311-322.	6.7	358

#	ARTICLE	IF	CITATIONS
451	Analysis of vascular gene expression in arthritic synovium by laser-mediated microdissection. <i>Arthritis and Rheumatism</i> , 2007, 56, 1094-1105.	6.7	25
452	Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients. <i>Arthritis and Rheumatism</i> , 2007, 56, 1087-1093.	6.7	196
453	Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. <i>Arthritis and Rheumatism</i> , 2007, 56, 2755-2764.	6.7	153
454	Microparticles stimulate the synthesis of prostaglandin E <sub>2</sub> via induction of cyclooxygenase 2 and microsomal prostaglandin E synthase 1. <i>Arthritis and Rheumatism</i> , 2007, 56, 3564-3574.	6.7	82
455	Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2007, 56, 4203-4215.	6.7	168
456	The role of membrane lipids in the induction of macrophage apoptosis by microparticles. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2007, 12, 363-374.	2.2	54
457	Antisense strategies in degenerative joint diseases: Sense or nonsense? <i>Advanced Drug Delivery Reviews</i> , 2006, 58, 285-299.	6.6	13
458	Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. <i>Arthritis and Rheumatism</i> , 2006, 54, 214-225.	6.7	89
459	Technology Insight: gene transfer and the design of novel treatments for rheumatoid arthritis. <i>Nature Clinical Practice Rheumatology</i> , 2006, 2, 153-162.	3.2	8
460	The Potential of Adiponectin in Driving Arthritis. <i>Journal of Immunology</i> , 2006, 176, 4468-4478.	0.4	277
461	Microparticles as mediators of cellular cross-talk in inflammatory disease. <i>Autoimmunity</i> , 2006, 39, 683-690.	1.2	154
462	The -2518 Promotor Polymorphism in the MCP-1 Gene Is Associated with Systemic Sclerosis. <i>Journal of Investigative Dermatology</i> , 2005, 124, 92-98.	0.3	70
463	Nucleofection: a new, highly efficient transfection method for primary human keratinocytes*. <i>Experimental Dermatology</i> , 2005, 14, 315-320.	1.4	51
464	Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2005, 52, 856-864.	6.7	127
465	Linking angiogenesis to bone destruction in arthritis. <i>Arthritis and Rheumatism</i> , 2005, 52, 1346-1348.	6.7	59
466	Microparticles as regulators of inflammation: Novel players of cellular crosstalk in the rheumatic diseases. <i>Arthritis and Rheumatism</i> , 2005, 52, 3337-3348.	6.7	215
467	Cyclooxygenase- and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: An imbalance between proinflammatory and antiinflammatory lipid mediators. <i>Arthritis and Rheumatism</i> , 2005, 52, 3783-3791.	6.7	63
468	The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 2892-2897.	3.3	368

#	ARTICLE	IF	CITATIONS
469	Bucillamine Induces the Synthesis of Vascular Endothelial Growth Factor Dose-Dependently in Systemic Sclerosis Fibroblasts via Nuclear Factor- $\kappa$ B and Simian Virus 40 Promoter Factor 1 Pathways. <i>Molecular Pharmacology</i> , 2004, 65, 389-399.	1.0	22
470	Physiologic responses to hypoxia and implications for hypoxia-inducible factors in the pathogenesis of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2004, 50, 10-23.	6.7	101
471	Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2004, 50, 1468-1476.	6.7	158
472	Uncontrolled Expression of Vascular Endothelial Growth Factor and Its Receptors Leads to Insufficient Skin Angiogenesis in Patients With Systemic Sclerosis. <i>Circulation Research</i> , 2004, 95, 109-116.	2.0	276
473	Minimum information about a microarray experiment: Comment on the editorial by Firestein and Pisetsky. <i>Arthritis and Rheumatism</i> , 2003, 48, 861-861.	6.7	2
474	Elevated levels of leukotriene B4 and leukotriene E4 in bronchoalveolar lavage fluid from patients with scleroderma lung disease. <i>Arthritis and Rheumatism</i> , 2003, 48, 1639-1646.	6.7	49
475	THE MOLECULAR CONTROL OF ANGIOGENESIS. <i>International Reviews of Immunology</i> , 2002, 21, 33-49.	1.5	58
476	Physiologically low oxygen concentrations determined in fetal skin regulate hypoxia-inducible factor 1 and transforming growth factor $\beta$ 3. <i>FASEB Journal</i> , 2002, 16, 411-413.	0.2	71
477	Anti-Tumor Necrosis Factor- $\alpha$ Treatment Improves Endothelial Function in Patients With Rheumatoid Arthritis. <i>Circulation</i> , 2002, 106, 2184-2187.	1.6	559
478	Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. <i>Arthritis Research</i> , 2002, 4, R11.	2.0	230
479	Evidence of 5-lipoxygenase overexpression in the skin of patients with systemic sclerosis: A newly identified pathway to skin inflammation in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2001, 44, 1865-1875.	6.7	49
480	Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: Role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. <i>Arthritis and Rheumatism</i> , 2001, 44, 2665-2678.	6.7	154
481	Gene transfer of protective cytokines in rheumatoid arthritis. <i>Advances in Experimental Medicine and Biology</i> , 2001, 495, 231-240.	0.8	0
482	Is there a viral trigger for vascular manifestations in autoimmune diseases such as systemic sclerosis?. <i>BMC Meeting Abstracts</i> , 2001, 2, .	0.0	0
483	HLA-DQA1*0501 is associated with diffuse systemic sclerosis in Caucasian men. <i>Arthritis and Rheumatism</i> , 2000, 43, 2005-2010.	6.7	63
484	Activation of the IL-4 STAT Pathway in Rheumatoid Synovium. <i>Journal of Immunology</i> , 2000, 164, 3894-3901.	0.4	39
485	Increased serum levels of antibodies against human cytomegalovirus and prevalence of autoantibodies in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1999, 42, 389-392.	6.7	92
486	P068 &lt;br /&gt; Design of a randomized, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCISâ,c). <i>QJM - Monthly Journal of the Association of Physicians</i> , 0, , .	0.2	0

#	ARTICLE	IF	CITATIONS
487	Corrigendum to: Digital pitting scars are associated with a severe disease course and death in systemic sclerosis: a study from the EUSTAR cohort. <i>Rheumatology</i> , 0, , .	0.9	0
488	Late Skin Fibrosis in Systemic Sclerosis: A Study from the EUSTAR Cohort. <i>Rheumatology</i> , 0, , .	0.9	3